Cyclerion stock cut in half after disappointing sickle cell trial results
October 14, 2020 at 11:39 AM EDT
The Cambridge biotech has stopped work on its sophomore drug after it exhibited a lackluster effect in a 70-person study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|